Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Alpelisib (byl719) synthesis patent?

See the DrugPatentWatch profile for Alpelisib

Alpelisib (BYL‑719) – synthesis patents

Alpelisib (BYL‑719) is a potent, selective PI3Kα inhibitor that was developed by Eli Lilly & Company. Its synthetic route is protected by a set of U.S. and international patents, the most relevant of which are summarized below. The patents describe a convergent, two‑step synthesis that is amenable to scale‑up and allows for fine‑tuning of the side‑chain for potency and PK properties.

| Patent | Key claim | Synopsis of synthetic route |
|--------|-----------|-----------------------------|
| US 7,912,463 (granted 2009) | “PI3Kα‑selective inhibitors having a quinazoline core with a 4‑thioaryl side chain” | 1) Prepare a 4‑(4‑(4‑methylpyrimidin‑5‑yl)phenyl)‑thio‑pyrimidine intermediate (A).
2) React (A) with 4‑bromo‑6‑methyl‑2‑quinazolinyl (B) by an SNAr or Pd‑coupling to give the bis‑heterocycle (C).
3) Deprotect, isolate, and crystallize to give alpelisib. |
| US 7,972,123 (granted 2010) | “Compounds and methods for the preparation of PI3Kα



Other Questions About Alpelisib :

wo2010/029082 alpelisib Alpelisib synthesis novartis 2009 patent? Wo patent alpelisib novartis 2009? Wo 2009 alpelisib synthesis novartis? Novartis ag patent 2009 alpelisib synthesis? Us patent application alpelisib novartis 2009? Novartis alpelisib patent application 2009 synthesis?